Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andamertinib Combined With Anlotinib in NSCLC After 3rd-Generation EGFR TKI
NCT07780578Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 2 trial of andamertinib in non-small cell lung cancer (NSCLC), sponsored by Fudan University. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
andamertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07780578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07780578.